Oral brain natriuretic peptide: a novel strategy for chronic protein therapy for cardiovascular disease.

Oral brain natriuretic peptide: a novel strategy for chronic protein therapy for cardiovascular disease. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Oral brain natriuretic peptide: a novel strategy for chronic protein therapy for cardiovascular disease. Abstract Text:

Alessandro Cataliotti,Horng H Chen,Kenneth D James,John C Burnett,

In 1956, secretory granules were detected via electron microscopy in the mammalian atria by Kisch. This remarkable discovery signaled the beginning of a new field of research that decades later has lead to the concept of the heart as an endocrine organ and the establishment of the natriuretic peptide (NP) system. In 1981, deBold and colleagues identified from the atrial myocardium the first member of the NP family, atrial NP. Thereafter, new members of this growing family of cardiac hormones were identified and investigated. The successful story of B-type or brain NP (BNP), from its discovery to its use in the diagnosis and prognosis of cardiovascular diseases and later as a tool in the treatment of acute congestive heart failure, have since taken place. However, the use of peptides as chronic therapies has been limited by enzymatic degradation. Chronic administration of BNP, particularly in disease states like hypertension and early heart failure, could be effective as an antihypertensive therapy and in delaying progression of cardiac disease. To date, the use of BNP is limited to patients with acute decompensated heart failure, but new strategies are under investigation to extend the use of chronic BNP in less severe stages of cardiovascular diseases. Innovative technologies have been recently developed that allow protection of proteins from enzymatic degradation, making feasible oral administration of small proteins such as BNP. This review will focus on the potential role of BNP as a new chronic therapeutic strategy in the treatment of cardiovascular diseases and will summarize our recent report of the development and in vivo evaluation of orally active human BNP.

Oral brain natriuretic peptide: a novel strategy for chronic protein therapy for cardiovascular disease. Publishing Authors By Initials

A Cataliotti,HH Chen,KD James,JC Burnett,

For similar hormones, hormone substitutes, and hormone antagonists: hormones: peptide hormones: natriuretic peptides: natriuretic peptide, brain research abstracts see: hormones, hormone substitutes, and hormone antagonists: hormones: peptide hormones: natriuretic peptides: natriuretic peptide, brain research

PUBMED ID PMID:

MEDLINE DATE:

Oral brain natriuretic peptide: a novel strategy for chronic protein therapy for cardiovascular disease. Journal Published:

PUBLICATION TYPE: Review

Journal: Trends in cardiovascular medicine

VOLUME: 17

Page Numbers: 10-4

Journal Abbreviation: Trends Cardiovasc. Med.

ISSN: 1050-1738

DAY: 3

MONTH: Jan

YEAR: 2007

Oral brain natriuretic peptide: a novel strategy for chronic protein therapy for cardiovascular disease. Information

Number of References: 27

LANGUAGE: eng

NlmUniqueID: 9108337

Oral brain natriuretic peptide: a novel strategy for chronic protein therapy for cardiovascular disease. Keywords Mesh Terms:

KEYWORDS: Natriuretic Peptide, Brain

MESH TERMS: chemistry

Chemical & Substance for Abstract: Oral brain natriuretic peptide: a novel strategy for chronic protein therapy for cardiovascular disease. Information

Substance Name: Natriuretic Peptide, Brain

Registry Number: 114471-18-0

Grant and Affiliation Information for Oral brain natriuretic peptide: a novel strategy for chronic protein therapy for cardiovascular disease.

AFFILIATION: Cardiorenal Research Laboratory and Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MN 55905, USA. cataliotti.alessandro@mayo.edu

Country: United States

AGENCY: United States NHLBI

GRANT: P01 HL76611

ACRONYM: HL

MEDLINETA: Trends Cardiovasc Med

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Oral brain natriuretic peptide: a novel strategy for chronic protein therapy for cardiovascular disease Related Publications

• A method for isolating living polymorphonuclear leukocytes from peripheral blood.
• An early regime for severe finger injuries.
• Anomalous channel between aorta and right ventricle; report of a case.
• Association between maternal exposure to ambient air pollutants during pregnancy and fetal growth restriction.
• BNP-induced activation of cGMP in human cardiac fibroblasts: interactions with fibronectin and natriuretic peptide receptors.
• Cystic emphysema of the lungs.
• Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation.
• Distinct roles for renal particulate and soluble guanylyl cyclases in preserving renal function in experimental acute heart failure.
• Does androgen suppression plus radiation therapy lead to changes in penile length in prostate cancer patients?
• Effectiveness of repellents applied to clothing for protection against salt-marsh mosquitoes.
• Erectile function outcomes in the current era of anatomic nerve-sparing radical prostatectomy.
• Erythropoietin receptor expression in the human urogenital tract: immunolocalization in the prostate, neurovascular bundle and penis.
• Ethical considerations in the use of DNA for the diagnosis of diseases.
• FK506 and sildenafil promote erectile function recovery after cavernous nerve injury through antioxidative mechanisms.
• Large-scale purification and crystallization of adenovirus hexon.
• MRC trials in acute myeloblastic luekemia: Where have we got to?
• Meta-Analysis of Neuropsychological Symptoms of Adolescents and Adults with PKU.
• Molecular Pharmacotherapeutic Targeting of PDE5 for Preservation of Penile Health.
• NADPH oxidase: recent evidence for its role in erectile dysfunction.
• Oral brain natriuretic peptide: a novel strategy for chronic protein therapy for cardiovascular disease.
• Periodically poled BaMgF(4) for ultraviolet frequency generation.
• Refractivity of nitrogen gas in the vacuum ultraviolet.
• Review of meningioma histopathology.
• Rights and the reality of healthcare charging in the United Kingdom.
• Roaches; how to identify and principles of control.
• Sapropterin dihydrochloride (Kuvan/phenoptin), an orally active synthetic form of BH4 for the treatment of phenylketonuria.
• The perforated appendix.
• Unusual strangulated hernias in infants.
• Validation and feasibility of intraoperative three-dimensional transesophageal echocardiographic cardiac output.
• Vulnerable elders: when it is no longer safe to live alone.